Insider · CIK 0002026090
Sherry Korczynski
Files at AQST (Aquestive Therapeutics, Inc.). First filing Sep 11, 2026, latest Sep 11, 2026.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
AQST: Aquestive Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 0Weak | Aquestive Therapeutics, Inc. | $46k 8,750 shares | -4% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 9, 2026 | AQST Aquestive Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +8,750 | $2.65 | $23k | 244,439 | 31 d ago |
| Sep 9, 2026 | AQST Aquestive Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -8,750 | $5.22 | $46k | 235,689 | 31 d ago |
| Sep 9, 2026 | AQST Aquestive Therapeutics, Inc. | MOption exercise Non-Qualified Stock Option (right to buy)derivative10b5-1 | -8,750 | $0.00 | $0 | 26,250 | 31 d ago |
| Jun 9, 2025 | AQST Aquestive Therapeutics, Inc. | FTax withholding Common Stock | -2,714 | $3.54 | $9,608 | 156,858 | Jun 10, 2025 |
| Mar 7, 2025 | AQST Aquestive Therapeutics, Inc. | AGrant or award Common Stock | +90,000 | $0.00 | $0 | 165,000 | Mar 11, 2025 |
| Mar 7, 2025 | AQST Aquestive Therapeutics, Inc. | FTax withholding Common Stock | -5,428 | $2.65 | $14k | 159,572 | Mar 11, 2025 |
| Mar 7, 2025 | AQST Aquestive Therapeutics, Inc. | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +35,000 | $0.00 | $0 | 35,000 | Mar 11, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.